VISTA as a prospective immune checkpoint in gynecological malignant tumors: A review of the literature

被引:3
作者
Ren, Ran [1 ,2 ]
Chang, Xin [1 ,2 ,3 ]
Chen, Cong [1 ,2 ]
Yu, Hao [1 ,2 ]
Han, Lu [1 ,2 ]
机构
[1] Dalian Women & Childrens Med Grp, Dept Gynecol, Dalian 116033, Peoples R China
[2] Lab Early Diag & Biotherapy Malignant Tumors Child, Dalian 116011, Peoples R China
[3] Dalian Med Univ, Dept Grad, Dalian 116044, Peoples R China
来源
OPEN MEDICINE | 2023年 / 18卷 / 01期
关键词
VISTA; malignant tumors; tumor microenvironment; immunotherapy; OVARIAN-CANCER; IMMUNOTHERAPY; PLATINUM;
D O I
10.1515/med-2023-0866
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
V-domain Ig suppressor of T cell activation (VISTA), encoded by the human VSIR gene, is a B7 family checkpoint homologous to the programmed death-Ligand 1 sequence. In gynecologic malignancies, VISTA is abnormally expressed and regulates the tumor immune microenvironment, causing a high upregulation of VISTA expression in T-cells and myeloid cells in the tumor microenvironment and promoting tumor proliferation, progression, and immune tolerance. Here, we review the research progress of VISTA in ovarian, cervical, and endometrial cancers through its structure and immunomodulatory mechanism. The comprehensive study of VISTA is expected to improve the current problem of poor immunotherapeutic effects and provide new ideas for immune therapy in patients with gynecologic tumors.
引用
收藏
页数:6
相关论文
共 24 条
[1]   Differential Characteristics and Prognosis of PD-L1-Positive Endometrial Carcinomas: A Retrospective Chart Review [J].
Amarin, Justin Z. ;
Mansour, Razan ;
Al-Ghnimat, Sura ;
Al-Hussaini, Maysa .
LIFE-BASEL, 2021, 11 (10)
[2]  
[Anonymous], 2019, Proc Natl Acad Sci U S A., V116, P1692
[3]  
Blando J, Comparison of immune infiltrates in melanoma and pancreaticcancer highlights VISTA as a potential target in pancreatic cancer
[4]   Treatment of patients with recurrent epithelial ovarian cancer for whom platinum is still an option [J].
Buechel, M. ;
Herzog, T. J. ;
Westin, S. N. ;
Coleman, R. L. ;
Monk, B. J. ;
Moore, K. N. .
ANNALS OF ONCOLOGY, 2019, 30 (05) :721-732
[5]   Hypoxia-Induced VISTA Promotes the Suppressive Function of Myeloid-Derived Suppressor Cells in the Tumor Microenvironment [J].
Deng, Jie ;
Li, Jiannan ;
Sarde, Aurelien ;
Lines, J. Louise ;
Lee, Yu-Chi ;
Qian, David C. ;
Pechenick, Dov A. ;
Manivanh, Richard ;
Le Mercier, Isabelle ;
Lowrey, Christopher H. ;
Varn, Frederick S. ;
Cheng, Chao ;
Leib, David A. ;
Noelle, Randolph J. ;
Mabaera, Rodwell .
CANCER IMMUNOLOGY RESEARCH, 2019, 7 (07) :1079-1090
[6]   Efficacy and Safety of Avelumab for Patients With Recurrent or Refractory Ovarian Cancer Phase 1b Results From the JAVELIN Solid Tumor Trial [J].
Disis, Mary L. ;
Taylor, Matthew H. ;
Kelly, Karen ;
Beck, J. Thaddeus ;
Gordon, Michael ;
Moore, Kathleen M. ;
Patel, Manish R. ;
Chaves, Jorge ;
Park, Haeseong ;
Mita, Alain C. ;
Hamilton, Erika P. ;
Annunziata, Christina M. ;
Grote, Hans Juergen ;
von Heydebreck, Anja ;
Grewal, Jaspreet ;
Chand, Vikram ;
Gulley, James L. .
JAMA ONCOLOGY, 2019, 5 (03) :393-401
[7]  
Flies DB, 2020, Sci Rep., V1, P14372
[8]   The current status of immunotherapy in the treatment of primary advanced and recurrent endometrial cancer [J].
Fontenot, Virginia E. ;
Tewari, Krishnansu .
CURRENT OPINION IN OBSTETRICS & GYNECOLOGY, 2023, 35 (01) :34-42
[9]   VISTA Blockade Immunotherapy in a MULTI-Modal Approach to Triple Negative Breast Cancer (TNBC) in MICE and IMPACT on Microbiome [J].
Kang, J. ;
Pilones, K. A. ;
Daviaud, C. ;
Kraynak, J. ;
Rodriguez-Ruiz, M. E. ;
Demaria, S. ;
Park, J. E. ;
Xu, C. ;
Zhou, X. K. ;
Formenti, S. C. .
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2019, 105 (01) :S88-S89
[10]   VISTA expression on tumor-infiltrating inflammatory cells in primary cutaneous melanoma correlates with poor disease-specific survival [J].
Kuklinski, Lawrence F. ;
Yan, Shaofeng ;
Li, Zhongze ;
Fisher, Jan L. ;
Cheng, Chao ;
Noelle, Randolph J. ;
Angeles, Christina V. ;
Turk, Mary Jo ;
Ernstoff, Marc S. .
CANCER IMMUNOLOGY IMMUNOTHERAPY, 2018, 67 (07) :1113-1121